Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.

Industry: Medical - Devices
Sector: Healthcare
Headquarters: CN
CEO: Zhong Zhao
Listed since: Jul 5, 2021
Employees: 925

Market position

Day range

Current HK$20.50

HK$20.48HK$22.00

52-week range

Current HK$20.50

HK$17.10HK$28.00

Open: HK$22.00
Previous close: HK$21.04
Volume: 2.58M; 5.41× average
Average volume: 477.16K; Average daily volume
Market cap: 6.37B HKD
Beta: 0.3; Market reference 1
50-day average: HK$19.1592; +7.00% above average
200-day average: HK$22.166; -7.52% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 6.2B CNY
P/E (TTM): 18.69×
P/B (TTM): 1.86×
P/S (TTM): 4.56×
EV / EBITDA: 26.72×
Earnings yield: 3.64%
Free cash flow yield: 4.00%
Dividend yield: 1.76%

Profitability & efficiency

Gross margin: 73.18%
Operating margin: 24.34%
Net margin: 25.05%
Return on equity: 7.56%
Return on assets: 6.84%
Return on invested capital: 5.94%

Financial health

Debt / equity: 0.05×
Current ratio: 5.98×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

1.06B CNY+35.15%

Operating income

196.64M CNY+222.81%

Net income

244.37M CNY+143.75%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.06B CNY	782.48M CNY	527.75M CNY	334.09M CNY	177.91M CNY
Cost of goods sold	294.57M CNY	222.58M CNY	142.77M CNY	81.42M CNY	46.03M CNY
Gross profit	762.92M CNY	559.9M CNY	384.99M CNY	252.67M CNY	131.88M CNY
Research and development	246.78M CNY	233.23M CNY	261.01M CNY	233.46M CNY	168.1M CNY
Selling, general, and administrative	315.87M CNY	265.76M CNY	277.92M CNY	249.47M CNY	195.87M CNY
Operating expenses	562.65M CNY	499.02M CNY	541.51M CNY	474.86M CNY	349.94M CNY
Interest income	54.64M CNY	67.35M CNY	79.04M CNY	95.57M CNY	13.09M CNY
Interest expense	996.52K CNY	2.18M CNY	1.25M CNY	722K CNY	307K CNY
Depreciation and amortization	33.1M CNY	29.11M CNY	35.88M CNY	26.27M CNY	9.68M CNY
Operating income	196.64M CNY	60.92M CNY	−156.52M CNY	−208.4M CNY	−212.48M CNY
Net income	244.37M CNY	100.26M CNY	−78.73M CNY	−113.56M CNY	−199.69M CNY